Branched chain amino acid treatment of tardive dyskinesia in children and adolescents

Journal of Clinical Psychiatry

Volumn 65, Issue 1, 2004, Pages 92-96

  Richardson, Mary Ann ^a,b   Small, Arthur M ^b,c   Read, Laura L ^a   Chao, Helen M ^a,b   Clelland, James D ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c St Agatha Home   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; DYSKINESIA; FEMALE; HOSPITALIZATION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; AMINO ACIDS, BRANCHED-CHAIN; CHILD; DYSKINESIAS; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1442284529     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0116     Document Type: Article

References (36)

1. Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37:221-227 (Pubitemid 28099191)
2. Meiselas KD, Spencer EK, Oberfield R, et al. Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children. J Clin Psychopharmacol 1989;9:207-209 (Pubitemid 19155163)
3. Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-843 (Pubitemid 27250449)
4. Campbell M, Spencer EK. Psychopharmacology in child and adolescent psychiatry: a review of the past five years. J Am Acad Child Adolesc Psychiatry 1988;27:269-279 (Pubitemid 18137250)
5. Lapierre YD, Raval KJ. Pharmacotherapy of affective disorders in children and adolescents. Psychiatr Clin North Am 1989;12:951-961 (Pubitemid 20052355)
6. Campbell M, Grega DM, Green WH, et al. Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 1983;6:207-222 (Pubitemid 14235232)
7. Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991;148:1322-1328
8. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001;62:967-974 (Pubitemid 34007963)
9. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 23):30-38 (Pubitemid 32952692)
10. Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001;286:2547-2548
11. Goode E. Leading drugs for psychosis come under new scrutiny. New York Times. May 20, 2003;sect A:1
12. Richardson MA, Haugland G, Pass R, et al. The prevalence of tardive dyskinesia in a mentally retarded population. Psychopharmacol Bull 1986;22:243-249 (Pubitemid 16101364)
13. Richardson MA, Suckow R, Whittaker R, et al. The plasma phenylalanine/ large neutral amino acid ratio: a risk factor for tardive dyskinesia. Psychopharmacol Bull 1989;25:47-51 (Pubitemid 19179159)
14. Richardson MA, Reilly MA, Read LL, et al. Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women. Psychopharmacology (Berl) 1999;143:347-357 (Pubitemid 29222479)
15. Richardson MA, Bevans M, Weber J, et al. A dietary intervention decreases tardive dyskinesia symptoms. Presented at the 149th annual meeting of the American Psychiatric Association; May 4-9, 1996; New York, NY
16. Blomstrand E, Newsholme EA. Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle. Acta Physiol Scand 1992;146:293-298
17. Moldawer LL, Sakamoto A, Blackburn GL, et al. Alterations in protein kinetics produced by branched chain amino acid administration during infection and inflammation. In: Walser M, Williamson JR, eds. Metabolism and Clinical Implications of Branched Chain Amino and Ketoacids. New York, NY: Elsevier North Holland; 1981:533-539
18. Harper AE, Miller RH, Block KP. Branched chain amino acid metabolism. Annu Rev Nutr 1984;4:409-454
19. Malaisse WJ. Branched chain amino and keto acids as regulators of insulin and glucagon release. In: Adibi SA, Fekl W, Langenbeck U, et al, eds. Branched Chain Amino and Keto Acids in Health and Disease. Basel, Switzerland: Karger; 1984:119-133
20. Berry HK, Bofinger MK, Hunt MM, et al. Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine and leucine. Pediatr Res 1982;16:751-755 (Pubitemid 12046920)
21. Berry HK, Brunner RL, Hunt MM, et al. Valine, isoleucine, and leucine: a new treatment for phenylketonuria. Am J Dis Child 1990;144:539-543 (Pubitemid 20153407)
22. Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl) 1999;143:358-364 (Pubitemid 29222480)
23. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160:1117-1124 (Pubitemid 41070971)
24. Richardson MA, inventor; New York State Office of Mental Health, assignee. Treatment of tardive dyskinesia with leucine, isoleucine, valine, or mixtures thereof. US patent 5 393 784. February 28, 1995
25. Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979;64:171-179 (Pubitemid 9227085)
26. Lieberman J, Kane JM, Woerner M, et al. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984;20:382-386 (Pubitemid 14090995)
27. Richardson MA, Craig TJ. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 1982;139:341-343 (Pubitemid 12180190)
28. Richardson MA, Craig TJ, Branchey MH. Intra-patient variability in the measurement of tardive dyskinesia. Psychopharmacology (Berl) 1982;76:269-272
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
30. Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240-1243 (Pubitemid 30240471)
31. Richardson MA, Haugland G. Typicality and atypicality in the development of neuroleptic side effects in child and adolescent psychiatric patients. In: Richardson MA, Haugland G, eds. Use of Neuroleptics in Children. Washington, DC: American Psychiatric Press, Inc.; 1996:43-66
32. Gregory DM, Sovetts D, Clow CL, et al. Plasma free amino acid values in normal children and adolescents. Metabolism 1986;35:967-969 (Pubitemid 17184367)
33. Bancel E, Strubel D, Bellet H, et al. Effect of the age and the sex on plasma concentration of amino acids [in French]. Ann Biol Clin (Paris) 1994;52:667-670
34. Milsom JP, Morgan MY, Sherlock S. Factors affecting plasma amino acid concentrations in control subjects. Metabolism 1979;28:313-319 (Pubitemid 9144327)
35. Maguire GA, Riley GD, Franklin DL, et al. Risperidone for the treatment of stuttering. J Clin Psychopharmacol 2000;20:479-482 (Pubitemid 30463765)
36. Wu JC, Maguire G, Riley G, et al. Increased dopamine activity associated with stuttering. Neuroreport 1997;8:767-770 (Pubitemid 27128233)